

ASX RELEASE

6 November 2020

KAZIA ANNUAL GENERAL MEETING RESULTS

Sydney, 6 November 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals are attached.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported most recently at AACR in June 2020, and further data is expected in 2H 2020. Five additional studies are in start-up or ongoing in other forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States with the final data expected in the second half of calendar 2020. Interim data was presented most recently at the AACR conference in June 2020. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

For more information, please visit www.kaziatherapeutics.com.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

**Kazia Therapeutics Limited
2020 Annual General Meeting
Friday, 06 November 2020
Results of Meeting**



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1. Adoption of Remuneration Report	Ordinary	50,400,575 93.40%	3,438,148 6.37%	123,290 0.23%	833,397	50,523,865 93.63%	3,438,148 6.37%	833,397	Carried
2. Re-election of Bryce Carmine	Ordinary	56,044,445 99.37%	233,074 0.41%	126,230 0.22%	118,330	56,170,675 99.59%	233,074 0.41%	118,330	Carried
3. Adoption of Employee Share Option Plan	Ordinary	51,603,236 95.36%	2,387,219 4.41%	123,290 0.23%	681,665	51,726,526 95.59%	2,387,219 4.41%	681,665	Carried
4. Approval of grant of Options to Dr James Garner	Ordinary	49,970,093 92.12%	4,149,503 7.65%	124,471 0.23%	913,843	50,094,564 92.35%	4,149,503 7.65%	913,843	Carried
5. Approval of grant of Options to Mr Iain Ross	Ordinary	50,498,353 93.28%	3,443,354 6.36%	195,302 0.36%	1,603,402	50,693,655 93.64%	3,443,354 6.36%	1,603,402	Carried
6. Approval of grant of Options to Mr Bryce Carmine	Ordinary	50,820,572 93.71%	3,268,479 6.03%	139,958 0.26%	566,401	50,960,530 93.97%	3,268,479 6.03%	566,401	Carried
7. Approval of grant of Options to Mr Steven Coffey	Ordinary	50,626,705 93.36%	3,465,747 6.39%	133,557 0.25%	569,401	50,760,262 93.61%	3,465,747 6.39%	569,401	Carried
8. Ratification of prior issue of Placement Shares	Ordinary	38,220,330 96.43%	424,890 1.07%	989,957 2.50%	1,406,902	39,210,287 98.93%	424,890 1.07%	1,406,902	Carried
9. Increase in the maximum amount allowable for non-executive Directors' fees	Ordinary	50,842,686 94.10%	3,065,401 5.67%	123,290 0.23%	1,709,034	50,965,976 94.33%	3,065,401 5.67%	1,709,034	Carried
10. Approval of Additional Placement capacity under Listing Rule 7.1A	Special	53,278,151 95.23%	2,548,503 4.55%	123,290 0.22%	572,135	53,401,441 95.45%	2,548,503 4.55%	572,135	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.